RSS-Feed 2.0 Press Releases, News - Helmholtz-Zentrum Dresden-Rossendorf


EU research network aims to drive generation of nanostructures with finely focused ion beams

Press Release of 25.01.2021

A finely focused ion beam (FIB) is a very useful tool in nanotechnology and analytics. Until now, scientists have mainly used FIB technology to prepare samples for certain microscopic techniques, such as troubleshooting in the semiconductor industry. But FIBs can do much more. The EU funded COST network project “Focused Ion Technology for Nanomaterials - FIT4NANO”, initiated by the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), aims to bring together researchers and companies from all over Europe to jointly develop the technology and open up new applications.


Digital frontier runners: CASUS involved in development of the world's largest supercomputer Frontier

Press Release of 18.01.2021

For one year now, researchers from CASUS, the Center for Advanced Systems Understanding at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), have supported the work on the world's largest planned exascale computer Frontier. The collaboration with the University of Delaware is now yielding its first results: the researchers successfully tested their PIConGPU simulation software on one of the world's fastest graphics cards for high-performance computers – the recently released MI100 from AMD.


Solstice: Liquid metals for energy storage

Press Release of 07.01.2021

Reliable and economical systems for storing large amounts of energy are needed for industrial nations such as Germany to succeed in making strides toward a regenerative energy supply. An international team led by Tom Weier and Norbert Weber from the Institute of Fluid Dynamics at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) aims to bring such applications to a level in which they are ready for use. The SOLSTICE project strives to develop energy storage systems based on liquid sodium and zinc from January 2021 onwards. The European Union is funding the project with eight million Euros through the Horizon 2020 program.


Strahlender Helfer: HZDR und ROTOP stellen Radionuklid für Medikament zur Parkinson-Diagnostik her

Press Release of 05.01.2021

Die Parkinson-Krankheit ist nach Demenz die zweithäufigste Nervenerkrankung weltweit. Allein in Deutschland sind nach Angaben der Deutschen Gesellschaft für Parkinson und Bewegungsstörungen etwa 400.000 Menschen erkrankt. Parkinson ist zwar nicht heilbar. Bei frühzeitiger Diagnose bestehen inzwischen jedoch gute Therapiemöglichkeiten zur Linderung der Symptome. Das Helmholtz-Zentrum Dresden-Rossendorf (HZDR) ist seit kurzem Produzent des Radionuklids Iod-123, dem Ausgangsstoff für ein Radiopharmakon zur gezielten nuklearmedizinischen Diagnostik von Parkinson. Das eigentliche Medikament wird in einem zweiten Schritt in der ROTOP Radiopharmacy GmbH synthetisiert, einem in unmittelbarer Nachbarschaft angesiedelten Unternehmen.

RSS-Feed 2.0 RSS-Feed 2.0

× Zoomed image larger